5 July 2018

Tikomed granted permission for clinical trial in ALS by the Swedish Medical Product Agency and Ethical Review Board.

Viken, May 28th, 2018

TikoMed, a specialty pharmaceutical company focused on developing therapeutics for treating acute and degenerative neurological and ophthalmic diseases, is delighted to announce that the company has been granted permission for a clinical trial (Phase 2a) in ALS (Amyotrophic Lateral Sclerosis) at Sahlgrenska University Hospital by the Swedish Medical Product Agency and Ethical Review Board.

Anders Svenson M.D., Chief Medical Officer of TikoMed, commented, “Today, we present an important milestone, with the granted permission by the Swedish Medical Product Agency and Ethical Review Board for our first phase 2a clinical trial, and we look forward to start initiating the ALS clinical trial in the coming months at Sahlgrenska Univeristy Hospital. We believe the ILB technology has significant potential for ALS and we therefore look forward to the study outcome later this year.”

The study will be performed at and in collaboration with Sahlgrenska University Hospital, Gothenburg, Sweden. Assoc. Professor Lennart Persson, a world renowned key opinion leader, will be principal investigator.15 patients will be treated with ILB during a 4-week period.

Tikomed is also preparing for an ALS study with Birmingham University Hospital, UK. 15 patients will be treated with ILB during a 10-week period.

DATE
TBA

TIME
TBA

VENUE
TBA

OTHER NEWS

14 August 2018
TIKOMED Announce Start of ALS Study at Sahlgrenska University Hospital
VIKEN, Sweden, August 14, 2018 – ​TIKOMED, a specialty pharmaceutical company focused on developing therapeutics…
Read More
31 July 2018
TIKOMED is looking for a business project manager with great administrative skills
We are looking for you who are driven, focused and known to get things done.…
Read More
24 July 2018
TIKOMED is looking for an experienced Project Leader
We are looking for you who are passionate, skilled and with strong track record and…
Read More
SEE MORE